243 filings
Page 3 of 13
8-K
97so0t
14 Dec 22
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
4:31pm
8-K
y26pqh4g5cx4mso
7 Dec 22
Entry into a Material Definitive Agreement
5:06pm
424B5
b9dvw1 kum46cpsdoi
7 Dec 22
Prospectus supplement for primary offering
4:04pm
424B5
clzuzva1c6
6 Dec 22
Prospectus supplement for primary offering
5:07pm
8-K
vwib3y6n69c743mpo4aw
5 Dec 22
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer
7:08am
8-K
2q2lh4w7 nxcah8x
3 Nov 22
Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
4:03pm
8-K
8ltgsdjh
23 Sep 22
Termination of a Material Definitive Agreement
4:05pm
8-K
lrrm65zdsoa b3
8 Aug 22
Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
4:04pm
8-K
qqr6cy6
13 Jun 22
Syndax Pharmaceuticals Announces Appointment of
7:32am
8-K
grsckckx75ua3
11 May 22
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
tous2 90jv23st
9 May 22
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update
12:00am
DEFA14A
epu2w31do
30 Mar 22
Additional proxy soliciting materials
4:03pm
S-8
6k5ivuyq2 g41omj
1 Mar 22
Registration of securities for employees
5:30pm
8-K
fe0yb9hgosx3cwf
1 Mar 22
Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update
12:00am
8-K
p6fvm2
24 Feb 22
Departure of Directors or Certain Officers
7:03am